PhRMA’s ‘Better Way:’ Remember COVID Success, Tweak Part B, And Bash HR 3
Trade group’s new agenda offers few original solutions to tackle US drug costs, relying on old standbys and reminders of what medical innovation might be lost if industry is financially targeted by policy makers with a strong nod to drug manufacturers role the current pandemic.
You may also be interested in...
Pricing policies aimed at lowering Medicare Part B costs should be ‘relatively easy’ to accomplish but they wouldn’t be as effective in satisfying industry critics as reforms in Part D, securities analyst Geoffrey Porges says.
Biopharma draws a line in the sand on drug pricing reform and offers to come to the table, but given the fracturing support for Rx legislation within the Democratic caucus, industry may not have as much need to negotiate with Congress. More detail on industry’s latest proposals for lowering costs may come in the second half.
US Drug Pricing Bill’s Prospects Will Be Shaped By Whether Public Worries More About Access Than Cost
HR 3 has been re-introduced, and some provisions may be attached to the White House’s infrastructure bill, but the government price negotiation system envisioned by the bill may fail – if industry can convince Congress to focus on access to medicines, not their cost.